Our project partner, InSilicoTrials, has been awarded with the 2023 Innovation Radar Prize Established by the European Commission in AI and Smart Devices Category.
The Innovation Radar Prize, initiated by the European Commission in 2015, celebrates innovators who have received EU funding and are working to transition their innovations from the laboratory to the market. This year’s Innovation Radar Summit, held in Lisbon in partnership with Eura AG, Deal-room.co, the European Startup Nations Alliance (ESNA), Startup Lisboa, and Microsoft, showcased the most promising innovations that have the potential to transform industries and improve the quality of life for people across Europe.
The European Health and Digital Executive Agency (HaDEA) recently spotlighted InSilicoTrials as a finalist in this prestigious competition. They detailed in an article how three HaDEA beneficiaries, including InSilicoTrials, were among the 12 finalists. InSilicoTrials is actively involved in four projects funded under Horizon 2020 or Horizon Europe. Two out of four (first in the list) see also the participation of the VPH Institute:
SimCardioTest (Horizon 2020): SimCardioTest is an international project that brings together 10 organizations from 6 European countries and the United States. It aims to provide new insights into designing predictive tools for cardiac pathologies and to accelerate the uptake of computer simulations for testing medicines and medical devices.
In Silico World (Horizon 2020): Its aim is to accelerate the uptake of modelling and simulation technologies for the development and regulatory assessment of medicines and medical devices. The project will develop 11 solutions leveraging state-of-the-art computational technologies to treat osteoporosis, tuberculosis, multiple sclerosis, coronary stenosis, cerebral aneurysms, mammary carcinoma, and covid-19 infection.
METASTRA (Horizon Europe): The project is set to transform the way clinicians assess fracture risk in cancer patients with vertebral metastases and promises to provide personalised treatment recommendations based on robust computational models and improved patient stratification techniques.
BRAINTEASER (Horizon 2020): BRAINTEASER is a data science project that seeks to exploit the value of big data, including those related to health, lifestyle habits, and environment, to support patients with amyotrophic lateral sclerosis and multiple sclerosis and their clinicians.
Our congratulation to InSilicoTrials for this important achievement!
